Micro RNAs as a new therapeutic target towards leukaemia signalling

Megan Y. Murray; Stuart A. Rushworth; David J. MacEwan

doi:10.1016/j.cellsig.2011.09.021

Micro RNAs as a new therapeutic target towards leukaemia signalling

Megan Y. Murray, Stuart A. Rushworth, David J. MacEwan

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) have emerged as potentially useful and specific agents to regulate transcriptional control of many cellular genes. There is a real prospect that miRNA and other short-length RNA reagents could be useful in a therapeutic setting. Here we outline the control of miRNAs in acute myeloid leukaemia (AML) subtype of human leukaemia, and ask whether miRNA could be important either in the generation of an AML phenotype, or as a variety of agents to combat the disease in the clinic. The use of miRNAs as potential biomarkers of aberrant signalling pathways involved in AML oncogenesis is also discussed.

Original language	English
Pages (from-to)	363-368
Number of pages	6
Journal	Cellular Signalling
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/j.cellsig.2011.09.021
Publication status	Published - Nov 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cellsig.2011.09.021

Cite this

@article{dc36d1e1840447ad92d208ced5ab4fd9,

title = "Micro RNAs as a new therapeutic target towards leukaemia signalling",

abstract = "MicroRNAs (miRNAs) have emerged as potentially useful and specific agents to regulate transcriptional control of many cellular genes. There is a real prospect that miRNA and other short-length RNA reagents could be useful in a therapeutic setting. Here we outline the control of miRNAs in acute myeloid leukaemia (AML) subtype of human leukaemia, and ask whether miRNA could be important either in the generation of an AML phenotype, or as a variety of agents to combat the disease in the clinic. The use of miRNAs as potential biomarkers of aberrant signalling pathways involved in AML oncogenesis is also discussed.",

author = "Murray, {Megan Y.} and Rushworth, {Stuart A.} and MacEwan, {David J.}",

year = "2011",

month = nov,

doi = "10.1016/j.cellsig.2011.09.021",

language = "English",

volume = "24",

pages = "363--368",

journal = "Cellular Signalling",

issn = "0898-6568",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Micro RNAs as a new therapeutic target towards leukaemia signalling

AU - Murray, Megan Y.

AU - Rushworth, Stuart A.

AU - MacEwan, David J.

PY - 2011/11

Y1 - 2011/11

N2 - MicroRNAs (miRNAs) have emerged as potentially useful and specific agents to regulate transcriptional control of many cellular genes. There is a real prospect that miRNA and other short-length RNA reagents could be useful in a therapeutic setting. Here we outline the control of miRNAs in acute myeloid leukaemia (AML) subtype of human leukaemia, and ask whether miRNA could be important either in the generation of an AML phenotype, or as a variety of agents to combat the disease in the clinic. The use of miRNAs as potential biomarkers of aberrant signalling pathways involved in AML oncogenesis is also discussed.

AB - MicroRNAs (miRNAs) have emerged as potentially useful and specific agents to regulate transcriptional control of many cellular genes. There is a real prospect that miRNA and other short-length RNA reagents could be useful in a therapeutic setting. Here we outline the control of miRNAs in acute myeloid leukaemia (AML) subtype of human leukaemia, and ask whether miRNA could be important either in the generation of an AML phenotype, or as a variety of agents to combat the disease in the clinic. The use of miRNAs as potential biomarkers of aberrant signalling pathways involved in AML oncogenesis is also discussed.

U2 - 10.1016/j.cellsig.2011.09.021

DO - 10.1016/j.cellsig.2011.09.021

M3 - Article

VL - 24

SP - 363

EP - 368

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 2

ER -